Home/Filings/4/0001140361-23-018047
4//SEC Filing

White Mark Andrew 4

Accession 0001140361-23-018047

CIK 0001281895other

Filed

Apr 11, 8:00 PM ET

Accepted

Apr 12, 7:00 PM ET

Size

7.2 KB

Accession

0001140361-23-018047

Insider Transaction Report

Form 4
Period: 2023-04-04
White Mark Andrew
Chief Medical Officer
Transactions
  • Award

    Common Stock, par value $0.01

    2023-04-04+76,66276,662 total
  • Award

    Stock Option (Right to Buy)

    2023-04-04+57,73957,739 total
    Exercise: $17.41Exp: 2033-04-04Common Stock (57,739 underlying)
Footnotes (2)
  • [F1]Holdings are Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on April 4, 2024, with the remaining shares vesting in equal quarterly installments over the following two years.
  • [F2]This option represents a right to purchase a total of 57,739 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on April 4, 2024, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Documents

1 file

Issuer

ROCKET PHARMACEUTICALS, INC.

CIK 0001281895

Entity typeother

Related Parties

1
  • filerCIK 0001973240

Filing Metadata

Form type
4
Filed
Apr 11, 8:00 PM ET
Accepted
Apr 12, 7:00 PM ET
Size
7.2 KB